Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Survival following allogeneic transplant in patients with myelofibrosis
Gowin, Krisstina , Ballen, Karen K. , Ahn, Kwang Woo , Hu, Zhen‐Huan , Ali, Haris , Arcasoy, Murat O. , Devlin, Rebecca, Coakley, Maria , Gerds, Aaron T. , Jain, Tania , Kandarpa, Malathi , Komrokji, Rami S. , Luber, Kierstin, Michaelis, Laura C. , Patches, Sarah, Pariser, Ashley, Rampal, Raajit K. , Stein, Brady L. , Verstovšek, Srđan , Wadleigh, Martha , Aljurf, Mahmoud , Avalos, Belinda R. , Bashey, Asad, Beitinjaneh, Amer , Černý, Jan , Copelan, Edward A. , DeFilipp, Zachariah , Gadalla, Shahinaz M. , Ganguly, Siddhartha , Hashmi, Shahrukh K. , Kharfan‐Dabaja, Mohamed A. , Kindwall‐Keller, Tamila L. , Kröger, Nicolaus , Litzow, Mark R. , Marks, David I. , Nathan, Sunita , Pawarode, Attaphol , Rowe, Jacob M. , Savoie, Mary Lynn , Seo, Sachiko , Solh, Melhem , Tamari, Roni , Verdonck, Leo F. , Alyea, Edwin P. , Sobecks, Ronald , Scott, Bart L. , Nakamura, Ryotaro , Saber, Wael , Kroger, Nicolaus , Davenport, Ashley Pariser , Gerds, Aaron T , Jain, Tania , Gadalla, Shahinaz M , Verstovsek, Srdan , Komrokji, Rami S , Kroger, Nicolaus , Kröger, Nicolaus , Green, Michael, Gupta, Vikas , Hobbs, Gabriela , Kuykendall, Andrew , Masárová, Lucia , Talpaz, Moshe , Agrawal, Vaibhav , Díaz, Miguel Ángel , Bacher, Ulrike , Chhabra, Saurabh , Cutler, Corey S. , Grunwald, Michael R. , Lazarus, Hillard M. , Liesveld, Jane L. , Nishihori, Taiga , Olsson, Richard F. , Savani, Bipin N. , Yared, Jean A. , Popat, Uday R , Mesa, Ruben A.

Mayo Clinic

Blood Advances | May 8, 2020 | Volume: 4 | Issue: 9 | Pages: 1965-1973

10.1182/bloodadvances.2019001084 | PMID 32384540 Get It

Abstract Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0.26, P < .0001; DIPSS-Int-2 and higher: HR, 0.39, P < .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was superior with non-HCT therapies compared with HCT in the first-year post treatment arm assignment (HR, 0.16, P = .006). However, after 1 year, OS was not significantly different (HR, 1.38, P = .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001). In conclusion, long-term OS advantage with HCT was observed for patients with Int-1 or higher risk MF, but at the cost of early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased and became apparent with longer follow-up.
Paget disease of the breast: A national retrospective analysis of the US population
Huayllani, María T. , Restrepo, David J. , Advani, Pooja , Lu, Xiaona , Spaulding, Aaron , Ball, Colleen T. , McLaughlin, Sarah A. , Forte, Antonio J. , Boczar, Daniel , Spaulding, Aaron C. , Forte, Antonio Jorge , Spaulding, Aaron , Sisti, Andrea

Mayo Clinic

Breast Disease | May 8, 2020 | Volume: 39 | Issue: 3-4 | Pages: 119-126

10.3233/bd-200439 | PMID 32390594 Get It

BACKGROUND: Paget’s disease of the breast is rare. The National Cancer Database (NCDB) is one of the largest tumor databases in the United States. METHODS: We queried the NCDB to identify male and female patients with Paget’s disease of the breast who were treated from January 1, 2004, through December 31, 2015. No age limitations were applied. Descriptive statistical analysis and survival analysis were performed. RESULTS: We analyzed the demographic, disease, and treatment characteristics of 7,191 patients with Paget’s disease of the breast. The median (range) age was 64 (20–90) years. Only 2.1% of patients were men, and 85.4% were white. The most common treatment was complete mastectomy (65.3%), followed by partial mastectomy (30.3%). Tumor destruction was performed in 0.1% of patients, and 4.3% of patients did not undergo any surgery. We examined survival in the subset of 6,864 patients who were treated surgically with complete mastectomy or partial mastectomy. The 5-year survival rate after surgery was 82.5% (95% CI, 81.1%–83.9%). Factors associated with shorter survival were older age, black race/ethnicity, higher tumor grade, regional lymph node metastasis, higher cancer stage, metastatic cancer, and larger tumor size. CONCLUSIONS: Paget’s disease of the breast usually affects patients older than 60 years, and the most common treatment is complete mastectomy. The 5-year overall survival rate of patients with Paget’s disease of the breast is greater than 80% but is lower among older and black people.
Anticholinergic, anti‐depressant and other medication use is associated with clinically relevant oesophageal manometric abnormalities
Moosavi, Sarvee , Woo, Matthew , Jacob, Deepti A., Pradhan, Sarah , Wilsack, Lynn, Buresi, Michelle , Gupta, Milli , Al‐Awadh, Yacoub, Li, Dorothy, Andrews, Christopher N. , Andrews, Christopher N

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 8, 2020 | Volume: 51 | Issue: 11 | Pages: 1130-1138

10.1111/apt.15758 | PMID 32383253 Get It

Summary Background Medications can affect gastrointestinal tract motility. However, their effects on oesophageal motility in particular are often not as widely known or may be underestimated. Aim To review the effect of existing medication use on high‐resolution oesophageal manometry (HRM) in a ‘real‐world’ setting. Methods Adult patients with upper gut symptoms and normal endoscopy or imaging who had HRM over a 22‐month period were analysed. Achalasia and major disorders of peristalsis were excluded. All medications taken within 24 hours of the procedure were prospectively recorded and compared with HRM results, controlling for age, gender and proton pump inhibitor use. Results A total of 502 patients (323 female, mean age 51) were recruited. Of these, 41.2% had normal oesophageal HRM, while 41.4% had ineffective oesophageal motility (IOM) and 7.6% had oesophagogastric junction outflow obstruction (OGJOO). Serotonin/norepinephrine reuptake inhibitors (SNRI) and opioids were associated with significantly higher resting lower oesophageal sphincter pressure. Benzodiazepines and opioids were associated with elevated integrated relaxation pressure. SNRI and inhaled beta‐agonists were associated with increased distal contractile index, whereas calcium channel blockers were associated with a lower distal contractile index. Odds ratio of being on anticholinergics was higher in IOM patients vs normal (3.6, CI 1.2‐10.8). Odds ratio for anticholinergics, inhaled beta‐agonists, anticonvulsants, SNRIs and opioids (trend) were all > 3 for OGJOO patients vs normal. Conclusion Many medication classes are associated with abnormal HRM variables and diagnoses such as OGJOO and IOM; some of these associations are probably causal. These possible links should be taken into consideration during manometry interpretation.
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020
Mehta–Shah, Neha , Ansell, Stephen M. , Barnes, Jeffrey A. , Clemens, Mark W. , Fisher, Kristopher , Goodman, Aaron M. , Guitart, Joan , Halwani, Ahmad , Haverkos, Bradley M. , Hoppe, Richard T. , Jacobsen, Eric D. , Jagadeesh, Deepa , Lunning, Matthew A. , Olsen, Elise A. , Pro, Barbara, Rajguru, Saurabh, Shaver, Aaron C., Shustov, Andrei R., Sokol, Lubomir , Torka, Pallawi , Torres‐Cabala, Carlos A. , William, Basem M. , Zain, Jasmine , Dwyer, Mary A., Sundar, Hema, William, Basem , Torres-Cabala, Carlos , Hoppe, Richard T , Horwitz, Sarah McCue , Ai, Weiyun Z. , Barta, Stefan K , Doǧan, Ahmet , Goyal, Gaurav , Mehta, Amitkumar , Shanbhag, Satish , Sokol, Lubomir , Wilcox, Ryan A. , Kim, Youn H

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 7, 2020 | Volume: 18 | Issue: 5 | Pages: 522-536

10.6004/jnccn.2020.0022 | PMID 32380458 Get It

Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).
Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Saad, Ayman , Anand, Sarah , Bookout, Ryan, Couriel, Daniel R. , Stasi, Antonio Di , El‐Jawahri, Areej , Gutman, Jonathan A. , Ho, Vincent T. , Horwitz, Mitchell E. , Hsu, Joe L. , Dabaja, Mohamed Kharfan, Loren, Alison W. , MSCE, Meade, Javier Bolaños, Moreira, Jonathan , Nakamura, Ryotaro , Roddy, Julianna, Satyanarayana, Gowri, Tan, Carlyn , Tzachanis, Dimitrios , Burns, Jennifer L. , Pluchino, Lenora A. , Saad, Ayman , Lima, Marcos de , Bhatt, Vijaya Raj , Chen, George T , Giralt, Sergio , Juckett, Mark , MSCE, Mielcarek, Marco B. , Nieto, Yago , Schroeder, Mark A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 7, 2020 | Volume: 18 | Issue: 5 | Pages: 599-634

10.6004/jnccn.2020.0021 | PMID 32519831 Get It

Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor cells into patients with hematologic disorders with the goal of re-establishing normal hematopoietic and immune function. HCT is classified as autologous or allogeneic based on the origin of hematopoietic cells. Autologous HCT uses the patient’s own cells while allogeneic HCT uses hematopoietic cells from a human leukocyte antigen-compatible donor. Allogeneic HCT is a potentially curative treatment option for patients with certain types of hematologic malignancies, and autologous HCT is primarily used to support patients undergoing high-dose chemotherapy. Advances in HCT methods and supportive care in recent decades have led to improved survival after HCT; however, disease relapse and posttransplant complications still commonly occur in both autologous and allogeneic HCT recipients. Allogeneic HCT recipients may also develop acute and/or chronic graft-versus-host disease (GVHD), which results in immune-mediated cellular injury of several organs. The NCCN Guidelines for Hematopoietic Cell Transplantation focus on recommendations for pretransplant recipient evaluation and the management of GVHD in adult patients with malignant disease.
United States Patients’ Perspective of Living With Migraine: Country‐Specific Results From the Global “My Migraine Voice” Survey
Gibbs, Sarah N. , Shah, Shweta, Deshpande, Chinmay , Bensink, Mark , Broder, Michael S. , Dumas, Paula K., Buse, Dawn C. , Vo, Pamela, Schwedt, Todd J.

Mayo Clinic

Headache: The Journal of Head and Face Pain | May 5, 2020 | Volume: 60 | Issue: 7 | Pages: 1351-1364

10.1111/head.13829 | PMID 32369201 Get It

Background Migraine is associated with debilitating symptoms that can affect daily functioning. “My Migraine Voice” was a large, cross‐sectional, multi‐country online survey aimed at understanding disease burden directly from people with migraine. Objective This study reports on the social and economic impacts of migraine, specifically the impact on activities of daily living and the costs of migraine, from the point of view of people with migraine in the United States. Methods The online survey was administered to adults with a self‐reported diagnosis of migraine who experienced 4 or more monthly migraine days each month for the previous 3 months. Prespecified screening quotas were used so that 90% of respondents reported current or past use of preventive migraine medication, 80% of whom switched treatment (ie, changed their prescribed preventive medication at least once). The remaining 10% were preventive treatment naïve (ie, never used any prescribed preventive medication). Burden of migraine on activities of daily living and caregivers (eg, functional limitations, fear of next migraine attack, sleep problems) and economic burden (eg, out‐of‐pocket costs, impact on work productivity using the validated work productivity and activity impairment questionnaire) reported by respondents from the United States are presented. Results are stratified by employment status, migraine frequency (chronic vs episodic migraine), and history of preventive treatment. Results Thousand hundred and one individuals with migraine from the United States responded to the survey. Respondents reported limitations completing daily activities during all migraine phases, including during the premonitory/aura and postdrome phases. Most (761/1101 (69%)) relied on family, friends, or others for help with daily tasks and reported being helped a median of 9 days (25th percentile 5 days, 75th percentile 15 days) within the last 3 months. Respondents with chronic migraine reported being helped for more days (median 10 days, 25th percentile 5 days, 75th percentile 23 days) in the last 3 months. Almost all (962/1101 (87%)) experienced sleep difficulties and 41% (448/1101) (48% (336/697) of those with 2 or more preventive treatment failures) were very or extremely fearful of a next migraine attack. Median (25th percentile, 75th percentile) monthly out‐of‐pocket costs of $90.00 ($30.00, $144.00) in doctor’s fees (n = 504), $124.00 ($60.00, $234.00) in health insurance (n = 450), $40.00 ($20.00, $100.00) for prescriptions (n = 630), and $50.00 ($0.00, $100.00) for complementary therapies (n = 255) were reported. Those with 2 or more preventive treatment failures reported higher monthly out‐of‐pocket doctor fees (median $99.00 ($30.00, $150.00), n = 388). Among employed respondents (n = 661), migraine resulted in 22% absenteeism, 60% presenteeism, 65% work productivity loss, and 64% activity impairment. Conclusions Migraine impacts individuals’ activities of daily living, work‐life, and financial status, especially individuals with high needs, namely those with 4 or more monthly migraine days and prior treatment failures. People with migraine are impaired during all migraine phases, experience fear of their next migraine attack and sleep difficulties, and pay substantial monthly out‐of‐pocket costs for migraine. Burden is even greater among those who have had 2 or more preventive treatment failures. Impacts of migraine extend beyond probands to caregivers who help people with migraine with daily tasks, employers who are affected by employee absenteeism, presenteeism, and reduced productivity, and society which is burdened by lost and reduced economic productivity and healthcare costs.
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT
Holtan, Shernan G. , Wang, Tao , Hemmer, Michael, Arora, Mukta , Couriel, Daniel R. , Pidala, Joseph, Abdel‐Azim, Hisham , Ahmed, Ibrahim , Al‐Homsi, A. Samer, Aljurf, Mahmoud , Antin, Joseph H. , Askar, Medhat , Auletta, Jeffery J. , Daly, Andrew , DeFilipp, Zachariah , Gajewski, James , Hematti, Peiman , Hildebrandt, Gerhard , Inamoto, Yoshihiro , Martino, Rodrigo , Majhail, Navneet S. , Marks, David I. , Pawarode, Attaphol , Prestidge, Tim , Rangarajan, Hemalatha G. , Ringdén, Olle , Saad, Ayman , Schoemans, Hélène , Seo, Sachiko , Solh, Melhem , Spitzer, Thomas R. , Storek, Jan , Verdonck, Leo F. , Wirk, Baldeep , Cahn, Jean‐Yves , Weisdorf, Daniel J. , Saad, Ayman , Ringden, Olov , Weisdorf, Dan , Majhail, Navneet S , Martino, Rodrigo , Holtan, Shernan , Auletta, Jeffery J , Hematti, Peiman , Mehta, Rohtesh S. , Spellman, Stephen R. , Alousi, Amin Majid , Agrawal, Vaibhav , Bhatt, Vijaya Raj , Chee, Lynette Chui Yen , Chhabra, Saurabh , Gale, Robert Peter , Gergis, Usama , Hogan, William J. , Nishihori, Taiga , Olsson, Richard F. , Díaz, Miguel Ángel , Savani, Bipin N. , Schultz, Kirk R. , Teshima, Takanori , Yared, Jean A.

Mayo Clinic

Journal of Clinical Oncology | May 4, 2020 | Volume: 38 | Issue: 18 | Pages: 2062-2076

10.1200/jco.19.00396 | PMID 32364845 Get It

PURPOSE There is no consensus on the best choice of an alternative donor (umbilical cord blood [UCB], haploidentical, one-antigen mismatched [7/8]–bone marrow [BM], or 7/8-peripheral blood [PB]) for hematopoietic cell transplantation (HCT) for patients lacking an HLA-matched related or unrelated donor. METHODS We report composite end points of graft-versus-host disease (GVHD)–free relapse-free survival (GRFS) and chronic GVHD (cGVHD)–free relapse-free survival (CRFS) in 2,198 patients who underwent UCB (n = 838), haploidentical (n = 159), 7/8-BM (n = 241), or 7/8-PB (n = 960) HCT. All groups were divided by myeloablative conditioning (MAC) intensity or reduced intensity conditioning (RIC), except haploidentical group in which most received RIC. To account for multiple testing, P < .0071 in multivariable analysis and P < .00025 in direct pairwise comparisons were considered statistically significant. RESULTS In multivariable analysis, haploidentical group had the best GRFS, CRFS, and overall survival (OS). In the direct pairwise comparison of other groups, among those who received MAC, there was no difference in GRFS or CRFS among UCB, 7/8-BM, and 7/8-PB with serotherapy (alemtuzumab or antithymocyte globulin) groups. In contrast, the 7/8-PB without serotherapy group had significantly inferior GRFS, higher cGVHD, and a trend toward worse CRFS (hazard ratio [HR], 1.38; 95% CI, 1.13 to 1.69; P = .002) than the 7/8-BM group and higher cGVHD and trend toward inferior CRFS (HR, 1.36; 95% CI, 1.14 to 1.63; P = .0006) than the UCB group. Among patients with RIC, all groups had significantly inferior GRFS and CRFS compared with the haploidentical group. CONCLUSION Recognizing the limitations of a registry retrospective analysis and the possibility of center selection bias in choosing donors, our data support the use of UCB, 7/8-BM, or 7/8-PB (with serotherapy) grafts for patients undergoing MAC HCT and haploidentical grafts for patients undergoing RIC HCT. The haploidentical group had the best GRFS, CRFS, and OS of all groups.
Randomized Trial Evaluating Clinical Impact of RAPid IDentification and Susceptibility Testing for Gram-negative Bacteremia: RAPIDS-GN
Banerjee, Ritu , Komarow, Lauren , Virk, Abinash, Rajapakse, Nipunie , Dylla, Brenda L., Earley, Michelle, Lok, Judith J. , Kohner, Peggy C., Ihde, Sherry M., Cole, Nicolynn C., Hines, Lisa B., Reed, Katelyn A. , Chandrasekaran, Sukantha , Kanatani, Meganne, Curello, Jennifer, Arias, Rubi, Swearingen, William, Doernberg, Sarah B. , Patel, Robin , Dylla, Brenda, Kohner, Peggy, Ihde, Sherry, Cole, Nicolynn, Hines, Lisa, Reed, Katelyn, Patel, Robin , Virk, Abinash , Schuetz, Audrey N. , Garner, Omai B. , Maurice, Annabelle de St.

Mayo Clinic

Clinical Infectious Diseases | April 30, 2020 | Volume: 73 | Issue: 1 | Pages: e39-e46

10.1093/cid/ciaa528 | PMID 32374822 Get It

Abstract Background Rapid blood culture diagnostics are of unclear benefit for patients with gram-negative bacilli (GNB) bloodstream infections (BSIs). We conducted a multicenter, randomized, controlled trial comparing outcomes of patients with GNB BSIs who had blood culture testing with standard-of-care (SOC) culture and antimicrobial susceptibility testing (AST) vs rapid organism identification (ID) and phenotypic AST using the Accelerate Pheno System (RAPID). Methods Patients with positive blood cultures with Gram stains showing GNB were randomized to SOC testing with antimicrobial stewardship (AS) review or RAPID with AS. The primary outcome was time to first antibiotic modification within 72 hours of randomization. Results Of 500 randomized patients, 448 were included (226 SOC, 222 RAPID). Mean (standard deviation) time to results was faster for RAPID than SOC for organism ID (2.7 [1.2] vs 11.7 [10.5] hours; P &lt; .001) and AST (13.5 [56] vs 44.9 [12.1] hours; P &lt; .001). Median (interquartile range [IQR]) time to first antibiotic modification was faster in the RAPID arm vs the SOC arm for overall antibiotics (8.6 [2.6–27.6] vs 14.9 [3.3–41.1] hours; P = .02) and gram-negative antibiotics (17.3 [4.9–72] vs 42.1 [10.1–72] hours; P &lt; .001). Median (IQR) time to antibiotic escalation was faster in the RAPID arm vs the SOC arm for antimicrobial-resistant BSIs (18.4 [5.8–72] vs 61.7 [30.4–72] hours; P = .01). There were no differences between the arms in patient outcomes. Conclusions Rapid organism ID and phenotypic AST led to faster changes in antibiotic therapy for gram-negative BSIs. Clinical Trials Registration NCT03218397.
The Role of Antibody Testing for SARS-CoV-2: Is There One?
Theel, Elitza S. , Slev, Patricia, Wheeler, Sarah , Couturier, Marc Roger , Wong, Susan J. , Kadkhoda, Kamran , Wheeler, Sarah E

Mayo Clinic

Journal of Clinical Microbiology | April 29, 2020 | Volume: 58 | Issue: 8 | Pages: No page available

10.1128/jcm.00797-20 | PMID 32350047 Get It

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) brought with it rapid development of both molecular and serologic assays for identification of COVID-19 infections. While Food and Drug Administration (FDA) emergency use authorization (EUA) is required for clinical application of SARS-CoV-2 molecular tests, submission for EUA is currently a voluntary process for manufacturers of serologic assays. The absence of FDA oversight of serologic tests is concerning given that the commercially available serologic assays are highly variable, differing in their format, the antibody class detected, the targeted antigen, and the acceptable specimen types.
Returning Results in the Genomic Era: Initial Experiences of the eMERGE Network
Wiesner, Georgia L. , Appelbaum, Paul S. , Aufox, Sharon , Bland, Harris T. , Zawatsky, Carrie L. Blout , Clayton, Ellen Wright , Harr, Margaret , Henrikson, Nora B. , Hoell, Christin , Holm, Ingrid A. , Jarvik, Gail P. , Lammers, Philip E. , Larson, Eric B. , Lindor, Noralane M. , Marasà, Maddalena , Myers, Melanie F. , Peterson, Josh F. , Prows, Cynthia A. , Ralston, James D. , Rasouly, Hila Milo , Sharp, Richard R. , Smith, Maureen E. , Driest, Sara L. Van , Williams, Janet L. , Wynn, Julia , Leppig, Kathleen A. , Appelbaum, Paul , Bland, Sarah T , Clayton, Ellen Wright , Henrikson, Nora , Holm, Ingrid A , Milo Rasouly, Hila , Sharp, Richard R , Smith, Maureen E , Van Driest, Sara L , Williams, Janet L , Myers, Melanie F , Jarvik, Gail P , Peterson, Josh F , Marasa, Maddalena , Hoell, Christin , Rahm, Alanna Kulchak , Christensen, Kurt D. , Chung, Wendy K. , Green, Robert C. , Kullo, Iftikhar J. , Williams, Marc S

Mayo Clinic

Journal of Personalized Medicine | April 28, 2020 | Volume: 10 | Issue: 2 | Pages: 30

10.3390/jpm10020030 | PMID 32349224 Get It

A goal of the 3rd phase of the Electronic Medical Records and Genomics (eMERGE3) Network was to examine the return of results (RoR) of actionable variants in more than 100 genes to consenting participants and their healthcare providers. Each of the 10 eMERGE sites developed plans for three essential elements of the RoR process: Disclosure to the participant, notification of the health care provider, and integration of results into the electronic health record (EHR). Procedures and protocols around these three elements were adapted as appropriate to individual site requirements and limitations. Detailed information about the RoR procedures at each site was obtained through structured telephone interviews and follow-up surveys with the clinical investigator leading or participating in the RoR process at each eMERGE3 institution. Because RoR processes at each of the 10 sites allowed for taking into account differences in population, disease focus and institutional requirements, significant heterogeneity of process was identified, including variability in the order in which patients and clinicians were notified and results were placed in the EHR. This heterogeneity in the process flow for eMERGE3 RoR reflects the “real world” of genomic medicine in which RoR procedures must be shaped by the needs of the patients and institutional environments.